Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine

Claudia V. Martinez, Matt O. Old, Douglas K. Kwock, Shalla S. Khan, Joaquin J. Garcia, Christina S. Chan, Ramothea Webster, Meira S. Falkovitz-Halpern, Yvonne A. Maldonado

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A uracil-to-cytosine point mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunction with vaccine-associated paralytic poliomyelitis (VAPP). Direct RNA extraction and mutant analysis by polymerase chain reaction and restriction enzyme cleavage were used to identify this point mutation in clinical samples. A total of 238 stool samples were obtained from 28 healthy infants for 6 weeks after OPV vaccination. More than 25% of infants shed OPV3 in the week after vaccination, with a decrease on day 6. A second wave of OPV3 shedding occurred beginning the second week after vaccination and was maintained through the end of the study period. During the first week after vaccination, the proportion of nt 472 mutants in the shed OPV3 increased from undetectable to almost 100%. During the second shedding period, the proportion of nt 472 mutants remained close to 100%. These results suggest that selective mutation drives the VAPP-associated nt 472 point mutation for OPV3 in the human gastrointestinal tract.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalJournal of Infectious Diseases
Volume190
Issue number2
DOIs
StatePublished - Jul 15 2004

Fingerprint

Uracil Nucleotides
Oral Poliovirus Vaccine
Poliovirus
Cytosine
Point Mutation
Vaccination
Nucleotides
Poliomyelitis
Vaccines
Uracil
Gastrointestinal Tract
RNA
Polymerase Chain Reaction
Mutation
Enzymes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. / Martinez, Claudia V.; Old, Matt O.; Kwock, Douglas K.; Khan, Shalla S.; Garcia, Joaquin J.; Chan, Christina S.; Webster, Ramothea; Falkovitz-Halpern, Meira S.; Maldonado, Yvonne A.

In: Journal of Infectious Diseases, Vol. 190, No. 2, 15.07.2004, p. 409-416.

Research output: Contribution to journalArticle

Martinez, CV, Old, MO, Kwock, DK, Khan, SS, Garcia, JJ, Chan, CS, Webster, R, Falkovitz-Halpern, MS & Maldonado, YA 2004, 'Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine', Journal of Infectious Diseases, vol. 190, no. 2, pp. 409-416. https://doi.org/10.1086/421703
Martinez, Claudia V. ; Old, Matt O. ; Kwock, Douglas K. ; Khan, Shalla S. ; Garcia, Joaquin J. ; Chan, Christina S. ; Webster, Ramothea ; Falkovitz-Halpern, Meira S. ; Maldonado, Yvonne A. / Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. In: Journal of Infectious Diseases. 2004 ; Vol. 190, No. 2. pp. 409-416.
@article{a1d9f03d75eb4dbc9e3f3916246d0265,
title = "Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine",
abstract = "A uracil-to-cytosine point mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunction with vaccine-associated paralytic poliomyelitis (VAPP). Direct RNA extraction and mutant analysis by polymerase chain reaction and restriction enzyme cleavage were used to identify this point mutation in clinical samples. A total of 238 stool samples were obtained from 28 healthy infants for 6 weeks after OPV vaccination. More than 25{\%} of infants shed OPV3 in the week after vaccination, with a decrease on day 6. A second wave of OPV3 shedding occurred beginning the second week after vaccination and was maintained through the end of the study period. During the first week after vaccination, the proportion of nt 472 mutants in the shed OPV3 increased from undetectable to almost 100{\%}. During the second shedding period, the proportion of nt 472 mutants remained close to 100{\%}. These results suggest that selective mutation drives the VAPP-associated nt 472 point mutation for OPV3 in the human gastrointestinal tract.",
author = "Martinez, {Claudia V.} and Old, {Matt O.} and Kwock, {Douglas K.} and Khan, {Shalla S.} and Garcia, {Joaquin J.} and Chan, {Christina S.} and Ramothea Webster and Falkovitz-Halpern, {Meira S.} and Maldonado, {Yvonne A.}",
year = "2004",
month = "7",
day = "15",
doi = "10.1086/421703",
language = "English (US)",
volume = "190",
pages = "409--416",
journal = "The Journal of infectious diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine

AU - Martinez, Claudia V.

AU - Old, Matt O.

AU - Kwock, Douglas K.

AU - Khan, Shalla S.

AU - Garcia, Joaquin J.

AU - Chan, Christina S.

AU - Webster, Ramothea

AU - Falkovitz-Halpern, Meira S.

AU - Maldonado, Yvonne A.

PY - 2004/7/15

Y1 - 2004/7/15

N2 - A uracil-to-cytosine point mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunction with vaccine-associated paralytic poliomyelitis (VAPP). Direct RNA extraction and mutant analysis by polymerase chain reaction and restriction enzyme cleavage were used to identify this point mutation in clinical samples. A total of 238 stool samples were obtained from 28 healthy infants for 6 weeks after OPV vaccination. More than 25% of infants shed OPV3 in the week after vaccination, with a decrease on day 6. A second wave of OPV3 shedding occurred beginning the second week after vaccination and was maintained through the end of the study period. During the first week after vaccination, the proportion of nt 472 mutants in the shed OPV3 increased from undetectable to almost 100%. During the second shedding period, the proportion of nt 472 mutants remained close to 100%. These results suggest that selective mutation drives the VAPP-associated nt 472 point mutation for OPV3 in the human gastrointestinal tract.

AB - A uracil-to-cytosine point mutation at nucleotide (nt) 472 of Sabin oral poliovirus vaccine (OPV) type 3 is found in conjunction with vaccine-associated paralytic poliomyelitis (VAPP). Direct RNA extraction and mutant analysis by polymerase chain reaction and restriction enzyme cleavage were used to identify this point mutation in clinical samples. A total of 238 stool samples were obtained from 28 healthy infants for 6 weeks after OPV vaccination. More than 25% of infants shed OPV3 in the week after vaccination, with a decrease on day 6. A second wave of OPV3 shedding occurred beginning the second week after vaccination and was maintained through the end of the study period. During the first week after vaccination, the proportion of nt 472 mutants in the shed OPV3 increased from undetectable to almost 100%. During the second shedding period, the proportion of nt 472 mutants remained close to 100%. These results suggest that selective mutation drives the VAPP-associated nt 472 point mutation for OPV3 in the human gastrointestinal tract.

UR - http://www.scopus.com/inward/record.url?scp=3242730051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242730051&partnerID=8YFLogxK

U2 - 10.1086/421703

DO - 10.1086/421703

M3 - Article

C2 - 15216480

AN - SCOPUS:3242730051

VL - 190

SP - 409

EP - 416

JO - The Journal of infectious diseases

JF - The Journal of infectious diseases

SN - 0022-1899

IS - 2

ER -